UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 225

Sortiert nach

Axotomy-Induced Smad1 Activation Promotes Axonal Growth in Adult Sensory Neurons

The Journal of neuroscience, 2009-06, Vol.29 (22), p.7116-7123

2009

Volltextzugriff (PDF)

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)

Alzheimer's research & therapy, 2018-09, Vol.10 (1), p.96-96, Article 96

2018

Volltextzugriff (PDF)

Parallel discovery of Alzheimer's therapeutics

Science translational medicine, 2014-06, Vol.6 (241), p.241cm5

2014

Volltextzugriff (PDF)

A Role for Nogo Receptor in Macrophage Clearance from Injured Peripheral Nerve

Neuron (Cambridge, Mass.), 2007-03, Vol.53 (5), p.649-662

2007

Volltextzugriff (PDF)

Longitudinal biomarkers in amyotrophic lateral sclerosis

Annals of clinical and translational neurology, 2020-07, Vol.7 (7), p.1103-1116

2020

Volltextzugriff (PDF)

Lack of Enhanced Spinal Regeneration in Nogo-Deficient Mice

Neuron (Cambridge, Mass.), 2003-04, Vol.38 (2), p.213-224

2003

Volltextzugriff (PDF)

Genetic Deletion of the Nogo Receptor Does Not Reduce Neurite Inhibition in vitro or Promote Corticospinal Tract Regeneration in vivo

Proceedings of the National Academy of Sciences - PNAS, 2005-01, Vol.102 (4), p.1205-1210

2005

Volltextzugriff (PDF)

The dorsolateral corticospinal tract in mice: An alternative route for corticospinal input to caudal segments following dorsal column lesions

Journal of comparative neurology (1911), 2004-05, Vol.472 (4), p.463-477

2004

Volltextzugriff (PDF)

Carole Ho

Nature reviews. Drug discovery, 2016-12, Vol.15 (12), p.816-816

2016

Volltextzugriff (PDF)

Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration

Science translational medicine, 2017-06, Vol.9 (395)

2017

Volltextzugriff (PDF)

A blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

Molecular genetics and metabolism, 2022-02, Vol.135 (2), p.S55-S55

2022

Volltextzugriff (PDF)

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ

The Journal of neuroscience, 2012-07, Vol.32 (28), p.9677-9689

2012

Volltextzugriff (PDF)

DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers

Clinical pharmacology and therapeutics, 2020-02, Vol.107 (2), p.406-414

2020

Volltextzugriff (PDF)

COMPASS, a double-blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

Molecular genetics and metabolism, 2023-02, Vol.138 (2), p.106996, Article 106996

2023

Volltextzugriff (PDF)

Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses

Molecular genetics and metabolism, 2024-08, Vol.142 (4), p.108535, Article 108535

2024

Volltextzugriff (PDF)

Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease

JAMA neurology, 2022-06, Vol.79 (6), p.592

2022

Volltextzugriff (PDF)

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

Movement disorders, 2023-03, Vol.38 (3), p.386-398

2023

Volltextzugriff (PDF)

Interim 49-week results of a phase 1/2 study of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

Molecular genetics and metabolism, 2022-02, Vol.135 (2), p.S20-S21

2022

Volltextzugriff (PDF)

Revised criteria for the diagnosis and staging of Alzheimer’s disease

Nature medicine, 2024-08, Vol.30 (8), p.2121-2124

2024

Volltextzugriff (PDF)

Safety and pharmacokinetics of single ascending doses of TAK‐594/DNL593, a brain‐penetrant progranulin replacement therapy, in healthy volunteers: Interim results from Part A of a Phase 1/2 clinical trial

Alzheimer's & dementia, 2023-12, Vol.19 (S21), p.n/a

2023

Volltextzugriff (PDF)

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

JAMA neurology, 2023-10, Vol.80 (10), p.1051

2023

Volltextzugriff (PDF)

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Alzheimer's & dementia, 2024-06, Vol.20 (8), p.5143-5169

2024

Volltextzugriff (PDF)

Somatic outcomes in a phase 1/2 study of weekly intravenous DNL310 (brain-penetrant enzyme replacement therapy) in mucopolysaccharidosis type II

Molecular genetics and metabolism, 2024-02, Vol.141 (2), p.107782, Article 107782

2024

Volltextzugriff (PDF)

1 – 25 von 225

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(211)
Mit Volltextzugriff
(201)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Axotomy-Induced Smad1 Activation Promotes Axonal Growth in Adult Sensory Neurons

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)

Parallel discovery of Alzheimer's therapeutics

A Role for Nogo Receptor in Macrophage Clearance from Injured Peripheral Nerve

New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures

Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients

Longitudinal biomarkers in amyotrophic lateral sclerosis

Lack of Enhanced Spinal Regeneration in Nogo-Deficient Mice

Genetic Deletion of the Nogo Receptor Does Not Reduce Neurite Inhibition in vitro or Promote Corticospinal Tract Regeneration in vivo

The dorsolateral corticospinal tract in mice: An alternative route for corticospinal input to caudal segments following dorsal column lesions

Carole Ho

Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration

A blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ

DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers

COMPASS, a double-blinded randomized phase 2/3 study of the efficacy and safety of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

Community consensus for Heparan sulfate as a biomarker to support accelerated approval in Neuronopathic Mucopolysaccharidoses

Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

Interim 49-week results of a phase 1/2 study of intravenous DNL310 (brain-penetrant enzyme replacement therapy) in MPS II

Revised criteria for the diagnosis and staging of Alzheimer’s disease

Safety and pharmacokinetics of single ascending doses of TAK‐594/DNL593, a brain‐penetrant progranulin replacement therapy, in healthy volunteers: Interim results from Part A of a Phase 1/2 clinical trial

Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Somatic outcomes in a phase 1/2 study of weekly intravenous DNL310 (brain-penetrant enzyme replacement therapy) in mucopolysaccharidosis type II

Suchergebnisse filtern